Landiolol, an ultra-short-acting &beta;1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 3

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Critical Care Medicine

ISSN

2220-3141

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Crit Care Med. Aug 4, 2015; 4(3): 251-257
Published online Aug 4, 2015. doi: 10.5492/wjccm.v4.i3.251

Full Size Figure Download Figure

Figure 2 Arterial pressure. Landiolol did not change atrial blood pressure. Results are expressed as mean ± SE.

Citation: Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med 2015; 4(3): 251-257
URL: https://www.wjgnet.com/2220-3141/full/v4/i3/251.htm
DOI: https://dx.doi.org/10.5492/wjccm.v4.i3.251

Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med 2015; 4(3): 251-257 [PMID: 26261777 DOI: 10.5492/wjccm.v4.i3.251]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.